FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)															
1. Name and Address of Reporting Person + HANNAH ALISON L.					2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner				
(Last) (First) (Middle) 9490 NEOGENOMICS WAY					3. Date of Earliest Transaction (Month/Day/Year) 06/10/2022								Officer (give title below) Other (specify below)				
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	IYERS, FI																
(Ci	ty)	(State)	(Zip)				Ta	ble I - No	on-De	rivative S	Securit	ies Acqui	red, Disposed	of, or Benefi	cially Owned	d	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Ye	Exe ar) any	2A. Deemed Execution Date, if any (Month/Day/Year)		Co (Ir	. Transaction ode (nstr. 8)		4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
				(IVIC				Code	V	Amount (A) or		r Price	(Instr. 3 and 4)				
Common Stock 06/		06/10/2022	2				A		15,556	A	\$ 0	107,433			D		
Reminder:	Report on a	separate line for eacl						P tł c	ersor nis for urren	rm are n tly valid	ot req OMB	uired to control	collection of respond unle number.				C 1474 (9-02
			Table l			ve Securit s, calls, w							Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		4. Transac Code	5. Numb of Deriva Securitie Acquired or Dispo of (D)	cquired (A) r Disposed f (D) nstr. 3, 4,		Exerc ion Da	te Underl		7. Title a	g Securities Derivative		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owner Form of Deriva Securi Direct or Indi	of Benefic Owner (ty: (Instr.		
				Code	v	(A)	(D)	Date Exercis	able	Expirati Date	ion	Title	Amount or Number of Shares		(Instr. 4)	(Instr.	4)
Stock Option (Right to Buy)	\$ 11.60							06/01/	/2019	06/01/	2023	Commo	1 3.017.00		3,017	D	
Stock Option (Right to Buy)	\$ 22.52							06/06/	/2020	06/06/	2026	Commo	1 4.269.00		4,269	D	
Stock Option (Right to Buy)	\$ 28.54							05/28/	2021	05/28/	2027	Commo Stock	1 3 448 00		3,448	D	
Stock Option (Right to Buy)	\$ 40.90							06/02/	2022	06/02/	2028	Commo Stock	1.3./14.00		3,714	D	
Stock Option (Right	\$ 8.10	06/10/2022		A		13,882		06/10/	2023	06/10/	2029	Commo	on 13,882.00	\$ 0	13,882	D	

Reporting Owners

to Buy)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
HANNAH ALISON L. 9490 NEOGENOMICS WAY FORT MYERS, FL 33912	X					

Signatures

/s/ Ali Olivo, Attorney-in-Fact	06/14/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit List:

Exhibit 24 - Limited Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Exhibit 24

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints William Bonello, Halley Gilbert, and Ali Olivo, and each of them individually, with full power of substitution, as the undersigned's true and lawf (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and (2) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of NeoGenomics, Inc. (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in acco (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and e (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally req The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the ex This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's hold [Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of January, 2022.

/s/ Alison L. Hannah